Predictive Potential of Glutathione S-Transferase Polymorphisms for Prognosis of Osteosarcoma Patients on Chemotherapy

  • Zhang, Shai-Lin (Department of Orthopaedics, The First Affiliated Hospital of Soochow University) ;
  • Mao, Ning-Fang (Department of Orthopaedics, Changhai Hospital, Second Military Medical University) ;
  • Sun, Jun-Ying (Department of Orthopaedics, The First Affiliated Hospital of Soochow University) ;
  • Shi, Zhi-Cai (Department of Orthopaedics, Changhai Hospital, Second Military Medical University) ;
  • Wang, Bing (Department of Orthopaedics, The First Affiliated Hospital of Soochow University) ;
  • Sun, Yong-Jian (Department of Traumatic Orthopedics, Nanfang Hospital, Southern Medical University)
  • Published : 2012.06.30


Objective: To evaluate the predictive value of glutathione S-transferase (GST) gene polymorphisms for the prognosis of osteosarcoma patients receiving chemotherapy. Methods: A total of 159 patients were included in our study between January 2005 and December 2007., with follow-up until January 2012. Genotyping was based upon the duplex polymerase-chain-reaction with the PCR-CTPP method. Results: At the time of diagnosis, 15.4% of the patients presented with metastasis, while 22.3% developed metastasis during follow-up. At the time of final analysis on January 2012, the median follow-up was 45.5 months. Patients with null GSTM1 and GSTT1 had a higher event free survival rate than non-null genotype, but no significant association was found between the two genotypes and prognosis of osteosarcoma. Individuals with GSTP1 Val/Val genotype tended to live shorter than with the IIe/IIe genotype, and we found a significantly higher risk of death from osteosarcoma (adjusted HR=2.35, 95% CI=1.13-4.85). Conclusion: The GSTP1 gene polymorphism may have an important role in the prognosis of osteosarcoma patients with chemotherapy. Further analyses with larger samples and more genes encoding metabolizing and DNA repair enzymes are warranted.


  1. Limmahakhun S, Pothacharoen P, Theera-Umpon N,et al (2011). Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev, 12, 1717-22.
  2. Listowsky I (1993). High capacity binding by glutathione S-tranferases and glucocorticoid resistance. In: Tew KD, Pickett CB, Mantle TJ, Mannervik B, Hayes JD, eds. Structure and Function of Glutathione Transferases. Boca Raton, FL: CRC Press, 199.
  3. Lo HW, Ali-Osman F (1997). Genomic cloning of hGSTP1${\ast}$C, an allelic human Pi class glutathione S-transferase gene variant, and functional characterization of its retinoic acid response elements. J Biol Chem, 272, 32743-9.
  4. Lu XF, Yang WL, Wan ZH, et al (2011). Glutathione S-transferase polymorphisms and bone tumor risk in China. Asian Pac J Cancer Prev, 12, 3357-60.
  5. Harries LW, Stubbins MJ, Forman D, et al (1997). Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis, 18, 641-4.
  6. Helzlsouer KJ, Selmin O, Huang H-Y, et al (1998). Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst, 90, 512-8.
  7. Hengstler JG, Arand M, Herrero ME, et al (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase, and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res, 154, 47-85.
  8. Howells RE, Dhar KK, Hoban PR, et al (2004). Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer, 14, 242-50.
  9. Ishimoto TM, Ali-Osman F (2002). Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics, 12, 543-53.
  10. Kelsey KT, Hankinson SE, Colditz GA, et al (1997). Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev, 6, 511-5.
  11. Ketterer B (1988). The protective role of glutathione transferases in mutagenesis and carcinogenesis. Mutat Res, 202, 343-61.
  12. Lee JM, Wu MT, Lee YC, et al (2005). Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res, 11, 4749-53.
  13. Ali-Osman F, Akande O, Antoun G, et al (1997). Molecular cloning, characterization, and expression in Escherichia coli of full length cDNAs of three human glutathione S-transferase pi gene variants. J Biol Chem, 272, 10004-12.
  14. Ambrosone CB, Freudenheim JL, Graham S, et al (1995). Cytochrome P450 1A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res, 55, 3483-5.
  15. Beeghly A, Katsaros D, Chen H, et al (2006). Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol, 100, 330-7.
  16. Bell DA, Taylor J, Paulson DF, et al (1993). Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst, 85, 1159-64.
  17. Black SM, Beggs JD, Hayes JD, et al (1990). Expression of human glutathione S-transferase in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J, 268, 309-15.
  18. Board PG, Webb GC, Coggan M (1989). Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 gene to chromosome bands 11q13 and 12q13-14. Ann Hum Genet, 53, 205-13.
  19. Choueiri TK, Garcia JA, Elson P, et al (2007). Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 110, 543-50.
  20. Deakin M, Elder J, Hendrickse C, et al (1996). Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 17, 881-4.
  21. Fuchs B, Zhang K, Schabel A, et al (2001). Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene, 278, 245-52.
  22. Mannervik B, Awasthi YC, Board PG, et al (1992). Nomenclature for human glutathione transferases. Biochem J, 282, 305-6.
  23. Marsh S, Paul J, King CR, et al (2007). Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol, 25, 4528-35.
  24. McIlwain CC, Townsend DM, Tew KD (2006). Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene, 25, 1639-48.
  25. Nagle CM, Chenevix-Trench G, Spurdle AB, et al (2007). The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer, 43, 283-90.
  26. Nakagawa K, Saijo N, Tsuchida S, et al (1990). Glutathione S-transferase p as a determinant of drug resistance in transfectant cell lines. J Biol Chem, 265, 4296-301.
  27. Nazar-Stewart V, Motulsky AG, Eaton DL, et al (1993). The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res, 53, 2313-8.
  28. Oldenburg J, Kraggerud SM, Cvancarova M, et al (2007). Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol, 25, 708-14.
  29. Pemble S, Schroeder KR, Spencer SR, et al (1994). Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J, 300, 271-6.
  30. Rosen G, Murphy ML, Huvos AG, et al (1976). Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer, 37, 1-11.<1::AID-CNCR2820370102>3.0.CO;2-3
  31. Seidegard J, Pero RW, Markowitz MM, et al (1990). Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis, 11, 33-6.
  32. Seidegard J, Vorachek WR, Pero RW, et al (1988). Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA, 85, 7293-7.
  33. Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42.
  34. Strange RC, Matharoo B, Faulder GC, et al (1991). The human glutathione S-transferases: a case-control study of the incidence of the GST1 theta phenotype in patients with adenocarcinoma. Carcinogenesis, 12, 25.
  35. Tew KD (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res, 54, 4313-20.
  36. Wang X, Zuckerman B, Pearson C, et al (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 287, 195-202.
  37. Watson MA, Stewart RK, Smith GBJ, et al (1998). Human glutathione S-transferase P1 polymorphisms: relationships to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 19, 275-80.
  38. Yuan Z-M, Smith PB, Brundrett RB, et al (1991). Glutathione conjugation with phosphoramide mustard and cyclophosphamide. Drug Metab Dispos, 19, 625-9.
  39. Zimniak P, Nanduri B, Pikula S, et al (1994). Naturally occurring human glutathione S-transferase GSTP-1 isoforms with isoleucin and valine in position 104 differ in enzymic properties. Eur J Biochem, 224, 893-9.

Cited by

  1. Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor vol.13, pp.11, 2012,
  2. The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis vol.24, pp.3, 2014,
  3. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy vol.35, pp.10, 2014,
  4. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma vol.11, pp.9, 2015,
  5. Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients pp.1792-1082, 2015,
  6. The pharmacogenomics of osteosarcoma vol.17, pp.1, 2017,
  7. Molecular mechanisms of chemoresistance in osteosarcoma (Review) vol.7, pp.5, 2014,